Treatment of Mesial Temporal Lobe Epilepsy with Amygdalohippocampal Stimulation: A Case Series and Review of the Literature

Min Bao,Guoming Luan,Jian Zhou
DOI: https://doi.org/10.3892/etm.2013.968
IF: 2.7
2013-01-01
Experimental and Therapeutic Medicine
Abstract:Deep brain stimulation (DBS) is being used with increasing frequency for the treatment of mesial temporal lobe epilepsy (MTLE). Here, we report two patients treated with amygdalohippocampal (AH)-DBS for drug-resistant temporal lobe epilepsy. Two patients with temporal lobe epilepsy were admitted to Beijing Sanbo Brain Hospital. The first patient was a 34-year-old male with a 31-year history of epileptic seizures. The second patient was a 27-year-old male with a 19-year history of drug-resistant epilepsy. The patients received a comprehensive presurgical workup and were considered unsuitable candidates for resective surgery. AH-DBS was recommended for the two patients. The last follow-up for patient 1 was 36 months after surgery and the final parameter settings were 3.6 mA, 450 μsec, 130 Hz and cycling with 60 sec on, 180 sec off. The last follow-up for patient 2 was 18 months after surgery and the final parameter settings were 2.6 mA, 450 μsec, 130 Hz and cycling with 60 sec on, 180 sec off. The patients experienced a seizure frequency reduction of 90 and 65%, respectively, with respect to the baseline. AH-DBS is a safe, micro-invasive alternative in patients with MTLE who are not candidates for resective surgery. It effectively reduces seizures without a negative effect on memory performance.
What problem does this paper attempt to address?